Literature DB >> 2225077

HIV-1 Tat protein trans-activates transcription in vitro.

R A Marciniak1, B J Calnan, A D Frankel, P A Sharp.   

Abstract

Tat protein of human immunodeficiency virus 1 is a potent trans-activator of viral gene expression. We show that purified Tat protein stimulates transcription from viral promoters greater than 10-fold in vitro. A Tat protein mutant that does not trans-activate in vivo did not stimulate transcription in vitro. Tat trans-activation required a functional TAR RNA sequence; trans-activation was competed by the addition of in vitro synthesized wild-type TAR RNA but not by mutant TAR RNAs. That Tat protein directly interacts with the TAR RNA during trans-activation in vitro was suggested by competition with Tat peptides. Preliminary evidence suggests the involvement of a cellular factor in recognition of TAR RNA during Tat trans-activation. Analysis of Tat trans-activation in vitro will provide new mechanistic insights into this process and allow a more detailed study of the relationship between Tat protein structure and function.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2225077     DOI: 10.1016/0092-8674(90)90145-5

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  124 in total

1.  Spt5 cooperates with human immunodeficiency virus type 1 Tat by preventing premature RNA release at terminator sequences.

Authors:  Cyril F Bourgeois; Young Kyeung Kim; Mark J Churcher; Michelle J West; Jonathan Karn
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

2.  Ubiquitination of RNA polymerase II large subunit signaled by phosphorylation of carboxyl-terminal domain.

Authors:  A Mitsui; P A Sharp
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

3.  Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro.

Authors:  C A Bohan; F Kashanchi; B Ensoli; L Buonaguro; K A Boris-Lawrie; J N Brady
Journal:  Gene Expr       Date:  1992

Review 4.  Mechanism of action of regulatory proteins encoded by complex retroviruses.

Authors:  B R Cullen
Journal:  Microbiol Rev       Date:  1992-09

5.  Circular dichroism and molecular modeling yield a structure for the complex of human immunodeficiency virus type 1 trans-activation response RNA and the binding region of Tat, the trans-acting transcriptional activator.

Authors:  E P Loret; P Georgel; W C Johnson; P S Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

6.  HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor.

Authors:  Maria A De Francesco; Manuela Baronio; Simona Fiorentini; Costantino Signorini; Carlo Bonfanti; Claudio Poiesi; Mikulas Popovic; Manuela Grassi; Emirena Garrafa; Luisa Bozzo; George K Lewis; Stefano Licenziati; Robert C Gallo; Arnaldo Caruso
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-08       Impact factor: 11.205

7.  Cooperation between upstream and downstream elements of the adenovirus major late promoter for maximal late phase-specific transcription.

Authors:  G Mondésert; C Kédinger
Journal:  Nucleic Acids Res       Date:  1991-06-25       Impact factor: 16.971

8.  The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation.

Authors:  M B Feinberg; D Baltimore; A D Frankel
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

9.  Central nervous system-derived cells express a kappa B-binding activity that enhances human immunodeficiency virus type 1 transcription in vitro and facilitates TAR-independent transactivation by Tat.

Authors:  J P Taylor; R J Pomerantz; G V Raj; F Kashanchi; J N Brady; S Amini; K Khalili
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

10.  Transcriptional trans activation by human immunodeficiency virus type 1 Tat requires specific coactivators that are not basal factors.

Authors:  C Suñé; M A García-Blanco
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.